10x Genomics, Inc.
TXG
$11.11
-$0.59-5.04%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 610.79M | 629.74M | 631.73M | 625.45M | 618.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 610.79M | 629.74M | 631.73M | 625.45M | 618.73M |
| Cost of Revenue | 196.00M | 210.13M | 222.99M | 221.31M | 209.41M |
| Gross Profit | 414.78M | 419.61M | 408.75M | 404.14M | 409.31M |
| SG&A Expenses | 343.24M | 338.33M | 339.04M | 344.71M | 343.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 803.24M | 806.16M | 820.06M | 832.59M | 818.46M |
| Operating Income | -192.46M | -176.42M | -188.32M | -207.14M | -199.73M |
| Income Before Tax | -177.70M | -175.92M | -233.22M | -256.91M | -248.76M |
| Income Tax Expenses | 4.93M | 6.63M | 6.56M | 7.39M | 6.34M |
| Earnings from Continuing Operations | -182.63 | -182.55 | -239.78 | -264.30 | -255.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -182.63M | -182.55M | -239.78M | -264.30M | -255.10M |
| EBIT | -192.46M | -176.42M | -188.32M | -207.14M | -199.73M |
| EBITDA | -156.58M | -139.57M | -151.07M | -168.92M | -164.22M |
| EPS Basic | -1.52 | -1.53 | -2.02 | -2.24 | -2.18 |
| Normalized Basic EPS | -0.91 | -0.80 | -0.88 | -0.99 | -0.96 |
| EPS Diluted | -1.52 | -1.53 | -2.02 | -2.24 | -2.18 |
| Normalized Diluted EPS | -0.91 | -0.80 | -0.88 | -0.99 | -0.96 |
| Average Basic Shares Outstanding | 481.79M | 478.76M | 475.76M | 472.40M | 468.62M |
| Average Diluted Shares Outstanding | 481.79M | 478.76M | 475.76M | 472.40M | 468.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
